As a customer-driven service company, we offer pharmaceutical clients comprehensive skills, ranging from process development, analytical method development, radiolabeling, cGMP- compliant scale-up and manufacturing of active ingredients, as well as regulatory support.
Girindus is the only company providing expertise in both oligonucleotide and small molecule API’s, combined with the unique offering of radioactive labelling.
We operate commercial scale oligonucleotide production at our FDA registered and inspected site in Cincinnati, Ohio, USA, which is also home to our laboratories and pilot plant facilities.
Girindus History:
2010
Focus on oligonucleotides further strengthened
2009
Completion of Oligonucleotides capacity expansion
2008
Girindus sells activities in Kuensebeck
2005
Solvay acquires majority stake in Girindus
2001
Girindus acquires manufacturing site in Cincinnati, Ohio, USA from Aventis
2000
IPO - Listing “Neuer Markt” Frankfurt, Germany
1999
Acquisition of API production facilities in Kuensebeck, Germany
1986
Girindus USA is established
1975
Girindus Germany and Switzerland are founded as independent service providers to the pharmaceutical industry
Today, over 70 associates work for Girindus worldwide.
